Tirzepatide with B12: what lab tests actually found

What the lab tests actually found

Researchers analysed compounded tirzepatide products that contained vitamin B12 and found the two ingredients had chemically bonded, creating a new molecule not present in the approved medicine. It appeared in every B12-containing sample tested, at up to 10 percent of the total peptide content, and it did not come apart under laboratory conditions designed to separate loosely attached things.

A laboratory analysis published in a drug-safety journal examined samples of compounded tirzepatide (medicine mixed by a pharmacy rather than manufactured and approved as a finished product) that also contained vitamin B12, drawn from sources on the United States market [1]. The finding was not a contaminant that had drifted in from dirty equipment. It was a new substance created by the two ingredients reacting with each other.

Chemists call that kind of product an adduct, meaning two molecules joined into one. The analysis reported the tirzepatide/B12 adduct in every B12-containing sample it tested, at levels reaching up to 10 percent of the total polypeptide content, which is the portion of the vial made up of peptide molecules [1]. Peptide mapping, a technique that chops a peptide into known pieces to work out where something is attached, suggested B12 binds at a specific point on the tirzepatide chain, the sixteenth amino acid, a lysine.

One detail matters more than it first appears. The researchers put the material through denaturing conditions, laboratory treatment that unfolds proteins and pulls apart anything merely clinging on, and the adduct stayed intact. It also survived a step in mass spectrometry (a method that measures molecular weight by turning molecules into charged particles) that would normally shake loose a weak association [1]. That is the evidence that this is a genuine chemical bond rather than two ingredients sitting next to each other in solution.

Eli Lilly, which makes the approved tirzepatide products, said it reproduced the finding in its own testing and published an open letter to prescribers and pharmacists calling for a recall of tirzepatide products containing untested additives [2]. Independent replication by the originator company is worth noting, because it removes the easiest way to dismiss a single laboratory's result.

Why is vitamin B12 in there at all?

B12 is not part of approved tirzepatide. Compounding pharmacies and telehealth sellers add it, usually marketed as helping with energy or nausea. No clinical trial has tested tirzepatide combined with B12 for any of those claims, and adding a second ingredient also creates a formulation that no regulator has reviewed.

This is the question most coverage skips, and it matters, because the adduct only exists if B12 is in the vial in the first place. The approved tirzepatide pens contain tirzepatide and standard inactive ingredients. They do not contain B12. Its presence is a choice made by whoever compounded the product, and it is typically marketed to patients as a bonus: extra energy, or help with the nausea that commonly accompanies this class of drug.

Look for the trial that supports that and you will not find one. Tirzepatide's efficacy and safety were established in large randomised trials of the drug alone, such as the SURPASS programme in type 2 diabetes and the SURMOUNT programme in obesity [6] [7]. None of those trials included B12, so there is no evidence that the combination works better, is tolerated better, or behaves the same way in the body. A pharmacy review of compounded incretin products makes the same point about the category as a whole: these combinations are sold as comparable to the approved medicines while undergoing no evaluation of their potency or impurity profile [4].

There is also a plainer commercial reason worth understanding. Adding an ingredient makes a product look distinct from the branded pen, which supports marketing it as something other than a copy. Whatever the motivation, the pharmacological consequence is the same: a beginner comparing a compounded tirzepatide/B12 vial against an approved pen is not comparing the same medicine in different packaging. It is a different formulation, and now demonstrably a different mixture of molecules.

What "up to 10 percent" means in a vial

Ten percent of polypeptide content means that in the samples with the most adduct, roughly one in ten peptide molecules was the new hybrid rather than tirzepatide itself. That fraction is not a trace contaminant. In an approved medicine, an unidentified substance at that level would not pass release testing.

Percentages in a chemistry paper are easy to skim past, so it helps to translate this one. The measurement was up to 10 percent of total polypeptide content, which means that in the most affected samples, about one in every ten peptide molecules in the vial was the adduct rather than tirzepatide [1]. Someone injecting that product is not receiving a dose of tirzepatide with a trace impurity. They are receiving a mixture, and roughly a tenth of the peptide in the mixture is a substance that has never been characterised.

For context on why that number is striking, approved medicines are held to impurity limits far below this, and any unidentified substance appearing at a whole percentage point triggers a requirement to identify it and demonstrate it is safe before the batch can be released. An approved product would not ship in this condition. That is not a technicality about paperwork; it is the entire mechanism by which a regulator knows what is in a syringe.

It also changes how you should read a dose. If a label says a vial contains a given quantity of tirzepatide and a tenth of the peptide present is actually something else, then the amount of active drug delivered is uncertain in a direction nobody has quantified. The same analytical work on compounded products has separately reported problems beyond impurities, including microbial contamination and high endotoxin levels, which are bacterial breakdown products that can trigger strong immune reactions [2]. Those are quality-control failures absent from approved manufacturing, and they compound the same underlying issue: nobody is checking.

What is still genuinely unknown

No patient harm has been attributed to the adduct, and the researchers say so directly. What remains unknown is whether it changes how tirzepatide binds its receptors, how it is absorbed or cleared, or whether it provokes an immune response. Unknown means unstudied here, not reassuring and not alarming.

This is where honest reporting matters, because the finding is easy to push in either direction. The authors state plainly that whether the adduct alters receptor binding, distribution, immune response, or any other aspect of how the drug behaves remains unknown [1]. To be equally clear about the other side: no patient harm has been attributed to this adduct. Nobody has documented an injury caused by it.

Both of those sentences are true at once, and holding them together is the whole skill. The concern is not that a harm has been demonstrated. The concern is that a molecule which nobody has studied is being injected at scale by people who believe they are taking a well-characterised medicine. Tirzepatide works by activating two gut-hormone receptors, GLP-1 and GIP, and B12 is attached at a specific point on the peptide chain; whether that attachment interferes with how the molecule fits those receptors is exactly the kind of question that would normally be answered before a product reached patients, not after.

The immune question deserves a sentence of its own, because it is the one that does not depend on the drug still working. Injecting a modified version of a peptide repeatedly is the classic circumstance in which the body can start recognising it as foreign, a phenomenon called immunogenicity. Whether that happens here is unstudied. The FDA has separately noted that it receives adverse-event reports for compounded semaglutide and tirzepatide, while pointing out that state-licensed pharmacies are not required to report such events, so the true count is certain to be undercounted [3]. An absence of documented harm from a system that does not systematically look for harm is weak reassurance.

How to tell whether this applies to you

This finding concerns compounded tirzepatide products containing vitamin B12, not the approved pens. If a vial came from a compounding pharmacy or telehealth seller, arrived as a powder or multi-dose vial, or lists B12 among its ingredients, it falls in scope. Approved pens do not contain B12.

The practical question is narrow and answerable. This finding is about compounded tirzepatide that contains vitamin B12. It is not about the approved, branded pens, which do not contain B12 and are made under manufacturing controls that test for exactly this class of problem.

A few signals put a product in scope. Approved tirzepatide arrives as a single-dose prefilled pen or a manufactured vial from the drug company, with the brand name on the carton. Compounded product typically arrives from a compounding pharmacy or a telehealth service, often as a multi-dose vial, sometimes as a powder to be mixed, and the ingredient list is where B12 shows up, occasionally described as cyanocobalamin or methylcobalamin, which are two forms of the vitamin. If B12 is on the label, this analysis is about the product in your hand.

If that describes your situation, the right move is a conversation, not a decision made from an article. Do not stop an injectable medicine based on something you read online, including this. Lilly's own recommendation to patients using these products is to contact their physician to discuss alternatives [2], and that is the appropriate step: the person who prescribed it can weigh your reasons for being on it against a quality concern in a way a general article cannot.

It is worth knowing how the legal picture got here, because it explains why these products are still circulating. Large-scale compounding of tirzepatide was permitted while the drug was on the FDA shortage list, and that permission lapsed in stages during 2025 once the shortage was declared resolved [5]. Compounded tirzepatide is no longer broadly lawful in the United States, yet it remains widely available through telehealth channels, which is precisely the gap in which an unreviewed formulation can reach a large number of people without anyone checking what is in it.